Image
Loading

Scroll

Molecular Genetics

Your genes speak, we translate

Molecular Genetics

Genekor specialises in molecular genetics.

Our company offers all the effective tools of molecular science to the physician for early detection, diagnosis, prognosis and personalised treatment of patients in oncology, cardiology, neurology and pharmacogenetics, using cutting-edge technology, as well as scientific experience & expertise.

 
 

The Company

GeneKor is a multinational company founded in 2007 and is engaged in the field of molecular biology and genetics. It operates a network of molecular biology laboratories worldwide with state-of-the-art equipment and its core activity is the development and conduct of molecular analyses.

Services

In our accredited laboratories we provide a variety of certified molecular genetics services, using cutting-edge technology for early detection, diagnosis, prognosis and personalised treatment of patients. The tests performed at Genekor enable doctors to practice personalised medicine on their patients.

We focus on oncology, rare diseases, cardiology, neurology and pharmacogenomics. Our aim is to achieve the most direct, valid and cost-effective diagnostic procedure in order to improve patient care.

The clinical expertise of Genekor focuses on:

0

Patients Worldwide

0

Countries

0

Doctors

0

Clinics

0

Publications

Greece - Romania - Cyprus - Turkey - United Arab Emirates - Belgium - Bosnia & Herzegovina - Bulgaria - Egypt - Georgia - Germany - Albania - Netherlands - Iraq - Ireland - United Kingdom - Kazakhstan - Kingdom Of Saudi Arabia - Kuwait - Kyrgyzstan -Lebanon - Libya - Serbia - Moldova - Montenegro - Iran - Nigeria - Oman - Poland - Qatar - Republic Of Kosovo - Algeria - Russia - North Macedonia - South Africa - Sudan - Switzerland - Bahrain - Ukraine - Azerbaijan - Jordan - USA - Uzbekistan - Latvia - Estonia - Lithuania - Czech Republic
Image

Scientific Publications

Neuroendocrine Breast Tumors: Could Multigene Assays Help in Guiding Treatment Decisions? Case Presentation

CHRISTOS MARKOPOULOS1, NIKOLAOS TSOULOS2, KONSTANTINOS AGIANNITOPOULOS2 and EVANGELIA KARAGIANNI3

Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice

Eirini Papadopoulou, PhD1 ; George Rigas, MD2; Elena Fountzilas, MD, PhD3 ; Anastasios Boutis, MD, PhD4; Stylianos Giassas, MD5; Nikolaos Mitsimponas, MD, MSc6; Danai Daliani, MD7 ; Dimitrios C Ziogas, […]

Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction

Dimitrios C. Ziogas 1,*,† , Eirini Papadopoulou 2,†, Helen Gogas 1 , Stratigoula Sakellariou 3, Evangellos Felekouras 4, Charalampos Theocharopoulos 1, Dimitra T. Stefanou 1, Maria Theochari 1, Ioannis Boukovinas […]

Genekor

Posters

  1. 2024

    PDF

    The importance of pre- and post-genetic counselling for genetic testing in hereditary cancer

  2. 2024

    PDF

    Low level constitutional mosaicism in breast cancer patients

  3. 2024

    PDF

    MAPPING OF GENE VARIANTS IN 7,587 SUBJECTS REFERRED FOR HEREDITARY CANCER

  4. 2022

    PDF

    Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer

  5. 2022

    PDF

    Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers.

  6. 2022

    PDF

    Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes

  7. 2022

    PDF

    Copy Number Variations (CNVs) and Hereditary Breast Cancer

  8. 2019

    PDF

    Multigene panel testing results for hereditary breast cancer - ESMO 2019

  9. 2018

    PDF

    Tumor Mutational Burden TMB - poster at ECCB 2018

  10. 2017

    PDF

    Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions

  11. 2016

    PDF

    BRCA Early Access program - poster at ECP

  12. 2014

    PDF

    CTRC-AACR San Antonio Breast Cancer Symposium 2014

  13. 2013

    PDF

    St. Gallen 2013 OncotypeDX

  14. 2013

    PDF

    St. Gallen 2013 BRCA

  15. 2012

    PDF

    EANO 2012

  16. 2012

    PDF

    ASCO 2012 EGFR

  17. 2012

    PDF

    ASCO 2012 ALK

  18. 2011

    PDF

    St. Gallen 2011

  19. 2011

    PDF

    ESMO 2011 ALK

  20. 2011

    PDF

    ESMO 2011 EGFR